Ray Therapeutics is a biotech company that develops optogenetic gene therapies for patients with blinding diseases.
Ray Therapeutics has raised $125.0M in total funding. The most recent round was Series B. The last funding was announced in April 2026.
Ray Therapeutics's investors include Norwest, Janus Henderson Investors, Novo Holdings, Adage Capital Management, Deerfield Management.
Ray Therapeutics is headquartered in San Diego, United States.
Ray Therapeutics is a biotech company that develops optogenetic gene therapies for patients with blinding diseases.
Ray Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ray Therapeutics — Funding & Investors." VCBacked, April 21, 2026, https://www.vcbacked.co/company/ray-therapeutics. Accessed July 20, 2026.
VCBacked. (2026). Ray Therapeutics — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/ray-therapeutics
{{cite web |title=Ray Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/ray-therapeutics |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated